FDA places partial hold on Biohaven’s epilepsy drug

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven’s epilepsy drug hit with FDA clinical hold

Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation

Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven partners with Ono in $100m IgG degrader deal

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights